$CUE
Cue Biopharma Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021055766 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $2.395M $700.0K $1.080M
YoY Change 242.14% -28.86% 2.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.100M $3.290M $3.870M
YoY Change 24.62% 19.64% 14.16%
% of Gross Profit
Research & Development $11.00M $7.517M $8.119M
YoY Change 46.3% 41.78% 18.23%
% of Gross Profit
Depreciation & Amortization $316.0K $199.0K $202.0K
YoY Change 58.79% 2.58% -1.46%
% of Gross Profit
Operating Expenses $15.41M $10.84M $12.02M
YoY Change 42.25% 34.13% 16.83%
Operating Profit -$13.02M -$10.13M -$10.94M
YoY Change 28.5% 42.81%
Interest Expense $25.00K $123.0K $134.0K
YoY Change -79.67% 24.24% 39.58%
% of Operating Profit
Other Income/Expense, Net $25.00K $100.0K $109.0K
YoY Change -75.0% -3.85% -10.66%
Pretax Income -$12.99M -$10.03M -$10.83M
YoY Change 29.53% 43.51% 18.93%
Income Tax
% Of Pretax Income
Net Earnings -$12.99M -$10.03M -$10.83M
YoY Change 29.53% 43.51% 13.77%
Net Earnings / Revenue -542.51% -1433.0% -1003.06%
Basic Earnings Per Share -$0.41
Diluted Earnings Per Share -$412.3K -$338.3K -$383.8K
COMMON SHARES
Basic Shares Outstanding 31.32M 28.43M
Diluted Shares Outstanding 31.32M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.63M $91.95M $85.08M
YoY Change -26.45% 191.65% 201.1%
Cash & Equivalents $67.63M $71.88M $59.90M
Short-Term Investments $0.00 $20.07M $25.18M
Other Short-Term Assets $1.851M $1.300M $2.200M
YoY Change 42.38% 30.0% 120.0%
Inventory
Prepaid Expenses
Receivables $771.0K $500.0K $1.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $70.26M $93.60M $88.40M
YoY Change -24.94% 183.72% 195.97%
LONG-TERM ASSETS
Property, Plant & Equipment $5.708M $1.739M $1.592M
YoY Change 228.23% -14.38% -27.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.912M $3.400M $3.300M
YoY Change -14.35% 328.75% 293.79%
Total Long-Term Assets $8.620M $13.00M $13.00M
YoY Change -33.69% 6.39% 9.35%
TOTAL ASSETS
Total Short-Term Assets $70.26M $93.60M $88.40M
Total Long-Term Assets $8.620M $13.00M $13.00M
Total Assets $78.88M $106.6M $101.4M
YoY Change -26.01% 135.79% 142.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.470M $1.100M $1.300M
YoY Change 124.55% -6.62% -43.21%
Accrued Expenses $7.622M $7.200M $8.300M
YoY Change 5.86% 363.02% 221.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.36M $14.20M $14.90M
YoY Change 8.13% 36.64% 32.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $4.800M $6.300M
YoY Change -100.0% -38.46% -38.24%
Total Long-Term Liabilities $0.00 $4.800M $6.300M
YoY Change -100.0% -38.46% -38.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.36M $14.20M $14.90M
Total Long-Term Liabilities $0.00 $4.800M $6.300M
Total Liabilities $15.36M $19.10M $21.20M
YoY Change -19.61% 5.02% -1.28%
SHAREHOLDERS EQUITY
Retained Earnings -$189.1M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.52M $87.55M $80.15M
YoY Change
Total Liabilities & Shareholders Equity $78.88M $106.6M $101.4M
YoY Change -26.01% 135.79% 142.84%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$12.99M -$10.03M -$10.83M
YoY Change 29.53% 43.51% 13.77%
Depreciation, Depletion And Amortization $316.0K $199.0K $202.0K
YoY Change 58.79% 2.58% -1.46%
Cash From Operating Activities -$6.627M -$7.690M -$6.870M
YoY Change -13.82% -16.5% 3.0%
INVESTING ACTIVITIES
Capital Expenditures -$13.00K -$350.0K -$140.0K
YoY Change -96.29% 1650.0%
Acquisitions
YoY Change
Other Investing Activities $2.000K $5.000M $0.00
YoY Change -99.96% 25.0% -100.0%
Cash From Investing Activities -$11.00K $4.650M -$140.0K
YoY Change -100.24% 16.83% -102.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 351.0K 15.01M 43.32M
YoY Change -97.66% 22.03% 1058.29%
NET CHANGE
Cash From Operating Activities -6.627M -7.690M -6.870M
Cash From Investing Activities -11.00K 4.650M -140.0K
Cash From Financing Activities 351.0K 15.01M 43.32M
Net Change In Cash -6.287M 11.97M 36.31M
YoY Change -152.52% 69.31% 1550.45%
FREE CASH FLOW
Cash From Operating Activities -$6.627M -$7.690M -$6.870M
Capital Expenditures -$13.00K -$350.0K -$140.0K
Free Cash Flow -$6.614M -$7.340M -$6.730M
YoY Change -9.89% -20.13% 0.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0061
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.978
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0054
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.980
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0131
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0156
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.996
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M26D
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2369000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31361995
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31361995
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189062000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
63520000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78875000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15413000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
83000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12993000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31515178
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13018000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12993000
CY2021Q3 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
482000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
72910000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12993000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
63520000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
80154000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2500000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
719000
CY2020Q3 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
35000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-83000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10031000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2062000
us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
567000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-7000
us-gaap Net Income Loss
NetIncomeLoss
-35777000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
63520000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54584000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8199000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1799000
us-gaap Profit Loss
ProfitLoss
-33682000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
804000
us-gaap Share Based Compensation
ShareBasedCompensation
8199000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
-2539000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
21000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-298000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
443000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
250000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
400000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
225000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1202000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
355000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-3354000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-945000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3513000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2406000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28192000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
913000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
21000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-10000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9949000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9108000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
10357000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
56682000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2061000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
567000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67633000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10003000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10003000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9995000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6323891
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72943000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10003000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
60005000
CY2020Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3477224
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.20
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4915000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2807000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2108000
us-gaap Depreciation
Depreciation
596000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
199000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5030899
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1026000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.41
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
307105
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
216137
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.84
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5533657
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.03
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2408000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3720000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
87000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of this lease agreement, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company also prepaid seven and one-half months’ rent pursuant to an amendment to the lease agreement executed on June 18, 2018.  These amounts were recorded to deposits and prepaid expenses, respectively, at December 31, 2018
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1312000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3633000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1223000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1285000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1225000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M15D

Files In Submission

Name View Source Status
0001564590-21-055766-index-headers.html Edgar Link pending
0001564590-21-055766-index.html Edgar Link pending
0001564590-21-055766.txt Edgar Link pending
0001564590-21-055766-xbrl.zip Edgar Link pending
cue-10q_20210930.htm Edgar Link pending
cue-10q_20210930_htm.xml Edgar Link completed
cue-20210930.xsd Edgar Link pending
cue-20210930_cal.xml Edgar Link unprocessable
cue-20210930_def.xml Edgar Link unprocessable
cue-20210930_lab.xml Edgar Link unprocessable
cue-20210930_pre.xml Edgar Link unprocessable
cue-ex101_109.htm Edgar Link pending
cue-ex102_110.htm Edgar Link pending
cue-ex311_7.htm Edgar Link pending
cue-ex312_6.htm Edgar Link pending
cue-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbbvq33aowdk000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending